Program
ocankitug
Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.
Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.
Drug pageOcankitug: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciencesits history only | 81 open or running | phase 2since Dec 13, 2021 | Apr 8, 2021 | none ahead |
| CSPC Pharmaceutical Group | 54 open or running | phase 3since Jan 11, 2026 | Mar 6, 2023 | Jul 1, 2027phase 2 · NCT07418736 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
CM326
, phase 3, as of Aug 20, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseCSPC (JMT-Bio) licensed it from Keymed, for mainland China, in all uses since November 2024 (respiratory diseases before).Agreed Nov 2021 · Source: Keymed Biosciences (HKEX announcement), Mar 24, 2025
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 2021CSPC (JMT-Bio) licensed it from KeymedLicenseMainland China, in all uses since November 2024 (respiratory diseases before) · agreed · Keymed Biosciences (HKEX announcement)
- Mar 6, 2023First study: phase 2 study in Moderate to Severe AsthmaFirst studyNCT05774340 · 207 enrolled · China
- Feb 29, 2024Named ocankitugINNProposed as its International Nonproprietary Name in WHO's List 130 · before, CM326
- Jan 11, 2026Phase 3 study in Moderate to Severe AsthmaPhase 3 reachedNCT07372287 · 230 planned · China
- Feb 4, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07418736 · 318 planned · China
- Feb 12, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07420257 · 212 planned
- Apr 14, 2026Phase 1 study in Healthy SubjectsNCT07560033 · 192 planned
Ahead
- Jul 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07418736
- Oct 30, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07420257
- Dec 31, 2028Primary completion: phase 3 study in Moderate to Severe AsthmaNCT07372287
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07560033Healthy Subjects | 1 | Not yet recruiting | Oct 1, 2026 | 192 |
| NCT07420257Chronic Rhinosinusitis With Nasal Polyps | 3 | Not yet recruiting | Oct 30, 2028 | 212 |
| NCT07418736Pulmonary Disease, Chronic Obstructive · China | 2 | Recruiting | Jul 1, 2027 | 318 |
| NCT07372287Moderate to Severe Asthma · China | 3 | Recruiting | Dec 31, 2028 | 230 |
| NCT05774340Moderate to Severe Asthma · China | 2 | UNKNOWN | Jan 2025 | 207 |
How it is read
Names in the registry
- “CM326”, 10 entries
- “CM326(formulation 1)”, 1 entry
- “CM326(formulation 2)”, 1 entry
- “CM326 injection”, 1 entry
- “CM326 dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Nasal Polyps, 3 studies
- Dermatitis, Atopic, 3 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.